Jefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects

0:00-9:36

He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company.

B-

BiotechTV - News

@biotechtvnews

#nuvationbiofounder #ceodavidhung #genros1inhibitor #lifesciences

The Nile